Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 213,148,320
  • Shares Outstanding, K 2,044,000
  • Annual Sales, $ 46,660 M
  • Annual Income, $ 14,850 M
  • EBIT $ 13,245 M
  • EBITDA $ 21,628 M
  • 60-Month Beta 0.58
  • Price/Sales 4.67
  • Price/Cash Flow 9.35
  • Price/Book 4.89

Options Overview Details

View History
  • Implied Volatility 17.30% ( +0.02%)
  • Historical Volatility 17.85%
  • IV Percentile 36%
  • IV Rank 37.33%
  • IV High 25.21% on 04/19/24
  • IV Low 12.60% on 05/16/24
  • Put/Call Vol Ratio 1.99
  • Today's Volume 748
  • Volume Avg (30-Day) 1,922
  • Put/Call OI Ratio 1.70
  • Today's Open Interest 46,487
  • Open Int (30-Day) 47,644

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.85
  • Number of Estimates 4
  • High Estimate 1.95
  • Low Estimate 1.76
  • Prior Year 1.53
  • Growth Rate Est. (year over year) +20.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
102.40 +1.38%
on 11/19/24
115.76 -10.33%
on 10/28/24
-9.98 (-8.77%)
since 10/25/24
3-Month
102.40 +1.38%
on 11/19/24
120.92 -14.15%
on 08/30/24
-15.34 (-12.87%)
since 08/26/24
52-Week
92.35 +12.41%
on 04/18/24
120.92 -14.15%
on 08/30/24
+5.67 (+5.78%)
since 11/24/23

Most Recent Stories

More News
Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View

This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’s PFE hemophilia drug Hympavzi (marstacimab). AstraZeneca’s AZN Tagrisso was recommended...

AZN : 66.36 (-0.06%)
JNJ : 154.52 (-0.81%)
LLY : 789.32 (+4.55%)
NVS : 103.81 (+0.26%)
PFE : 25.77 (-1.53%)
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics

Novartis NVS announced that it has increased its sales guidance for the mid-term. The company now expects total sales to witness a compound annual growth rate (CAGR) of 6% during 2023-2028 compared with...

NVS : 103.81 (+0.26%)
GILD : 91.35 (+0.95%)
PFE : 25.77 (-1.53%)
MEDIA STATEMENT - Novartis Canada disappointed with outcome of pCPA negotiations for metastatic castration resistant prostate cancer treatment PLUVICTOâ„¢

/CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is extremely disappointed that negotiations for PLUVICTOâ„¢ (lutetium (177Lu) vipivotide...

NVS : 103.81 (+0.26%)
Top Stock Reports for Netflix, Salesforce & Cisco

Tuesday, November 12, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix, Inc....

NFLX : 872.60 (+0.81%)
CSCO : 59.59 (+1.45%)
TSLA : 338.23 (-0.11%)
TTE : 57.54 (-1.24%)
NVS : 103.81 (+0.26%)
CRM : 343.18 (+1.20%)
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales

Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected third-quarter results despite lower sales from its lead drug, Eylea. Revenues climbed 11% to $3.72 billion, driven by growth in Eylea...

BAYRY : 4.9700 (-4.61%)
NVS : 103.81 (+0.26%)
REGN : 753.03 (+0.47%)
SNY : 48.28 (-0.14%)
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript

NVS earnings call for the period ending September 30, 2024.

NVS : 103.81 (+0.26%)
3 Absurdly Cheap Stocks That Pay High Dividends

These stocks are trading at less than 15 times their expected future profits.

MRK : 101.62 (+0.45%)
NVS : 103.81 (+0.26%)
GILD : 91.35 (+0.95%)
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen

For Immediate ReleaseChicago, IL – October 24, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVO : 106.13 (+1.50%)
NVS : 103.81 (+0.26%)
REGN : 753.03 (+0.47%)
PFE : 25.77 (-1.53%)
BIIB : 157.69 (-0.64%)
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen

For Immediate ReleaseChicago, IL – October 23, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVO : 106.13 (+1.50%)
NVS : 103.81 (+0.26%)
REGN : 753.03 (+0.47%)
PFE : 25.77 (-1.53%)
BIIB : 157.69 (-0.64%)
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates

The earnings season for the drug and biotech sector kicked off last week when bellwether Johnson & Johnson reported strong third-quarter results, beating estimates for earnings and sales. J&J consequently...

NVO : 106.13 (+1.50%)
NVS : 103.81 (+0.26%)
REGN : 753.03 (+0.47%)
PFE : 25.77 (-1.53%)
BIIB : 157.69 (-0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy,...

See More

Key Turning Points

3rd Resistance Point 105.02
2nd Resistance Point 104.56
1st Resistance Point 104.18
Last Price 103.81
1st Support Level 103.34
2nd Support Level 102.88
3rd Support Level 102.50

See More

52-Week High 120.92
Fibonacci 61.8% 110.01
Fibonacci 50% 106.63
Last Price 103.81
Fibonacci 38.2% 103.26
52-Week Low 92.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar